The U.S. has approved a groundbreaking weight-loss pill called Wegovy, which could potentially transform the healthcare industry. This pill is a version of the popular GLP-1 weight-loss drug Wegovy and has been given the green light for use in the U.S. The approval of this pill marks a significant milestone for the industry, as it has struggled to create effective pill versions of weight-loss injections for years.
Daniel Drucker, an endocrinologist at the University of Toronto, highlights the importance of having more options for people, as most individuals prefer taking a pill over regular injections. The pills could also improve access to the medication by reducing costs, as injections can be quite expensive.
Rozalina McCoy, an endocrinologist and internist at the University of Maryland, emphasizes that pills are easier to transport and produce, which could further increase access to these drugs. Novo Nordisk, the company behind the Wegovy pill, has seen promising results from its trials, with the highest dose of the pill resulting in a significant weight loss compared to a placebo.
GLP-1 drugs have revolutionized the treatment of metabolic diseases, but until now, they have mainly been available in the U.S. as injections. The approval of the Wegovy pill opens up new possibilities for individuals looking to manage their weight and improve their health.
The pill works similarly to the weekly injections, mimicking the activity of a gut hormone that helps people feel fuller and eat less. However, the pills must be taken on an empty stomach for optimal effectiveness. The side effects of the pills are similar to those of the injections, including nausea, diarrhea, and vomiting.
The Wegovy pill will be available in U.S. pharmacies and select telehealth providers in early January. The starting dose is expected to cost $149 per month out of pocket, with prices for higher doses to be shared in the new year. Other companies are also working on their own weight-loss pills, which could lead to more options in the market and potentially drive prices down.
Overall, the approval of the Wegovy weight-loss pill represents a significant advancement in the healthcare industry and could have a positive impact on individuals looking to manage their weight and improve their overall health. It is crucial to advocate for science now more than ever. As a longstanding subscriber to Scientific American, I have witnessed the impact of their work in shaping perspectives and fostering a sense of wonder for the universe. By supporting Scientific American, you contribute to the coverage of significant research and discoveries, shed light on threats to laboratories nationwide, and provide crucial support to scientists at all stages of their careers.
Subscribing to Scientific American grants access to essential news, engaging podcasts, informative infographics, insightful newsletters, captivating videos, stimulating games, and top-notch writing on scientific advancements. You can even gift a subscription to someone who shares your passion for science.
In a time when the value of science is often overlooked, it is more important than ever to stand up and emphasize why science matters. By supporting Scientific American, you join in the mission to showcase the significance of scientific research and innovation in our society.
I urge you to consider subscribing to Scientific American and becoming a part of the movement to champion science and its impact on our world. Together, we can ensure that science continues to be a driving force in shaping our future.
